Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients With Nail Psoriasis

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05072886

Enrollment

Registered

2021-10-11

Start date

2022-04-01

Completion date

2023-08-31

Last updated

2023-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail Psoriasis, Plaque Psoriasis

Brief summary

Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension phase where all patients will receive active drug for an additional 16 weeks followed by a 2 week nontreatment period.

Interventions

DRUGAT193

Topical applied to affected areas daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of nail psoriasis for at least 3 months preceding study entry * Diagnosis or history of plaque psoriasis or psoriatic arthritis * A female participant of childbearing potential must use appropriate contraceptive measures during the study period * A female participant of childbearing potential must have a negative urine pregnancy test result at screening * Written informed consent must be obtained before any study procedure is performed

Exclusion criteria

* Pregnant or breastfeeding * Diagnosis of other active skin or nail diseases or skin or nail infections (bacterial, fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis * History or evidence of a clinically significant disorder, condition, or disease that would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion in the judgment of the investigator

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-emergent adverse events	16 weeks

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026